Clinical Characteristics and Treatment Outcomes of Mycobacterium fortuitum Pulmonary Disease.
Mycobacterium fortuitum
outcome
treatment
Journal
Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614
Informations de publication
Date de publication:
17 08 2023
17 08 2023
Historique:
medline:
21
8
2023
pubmed:
10
7
2023
entrez:
10
7
2023
Statut:
ppublish
Résumé
We evaluated the clinical characteristics and treatment outcomes of 35 patients diagnosed with Mycobacterium fortuitum-pulmonary disease (M. fortuitum-PD). Prior to treatment, all isolates were sensitive to amikacin and 73% and 90% were sensitive to imipenem and moxifloxacin, respectively. Approximately two-thirds of the patients (24 of 35) remained stable without antibiotic treatment. Of 11 patients requiring antibiotic treatment, the majority (81%, 9 of 11) achieved a microbiological cure with susceptible antibiotics.
Identifiants
pubmed: 37428038
doi: 10.1128/spectrum.02051-23
pmc: PMC10433795
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0205123Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Chest. 2021 Aug;160(2):436-445
pubmed: 33621600
Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416
pubmed: 17277290
Clin Chest Med. 2015 Mar;36(1):13-34
pubmed: 25676516
Respir Med. 2008 Mar;102(3):437-42
pubmed: 17997087
Thorax. 1988 Feb;43(2):151-2
pubmed: 3353887
Br J Dis Chest. 1970 Apr;64(2):112-8
pubmed: 5432626
J Clin Pathol. 1993 Mar;46(3):271-2
pubmed: 8463423
Chest. 1987 Dec;92(6):1110-2
pubmed: 3479304
Eur Respir J. 2020 Jul 7;56(1):
pubmed: 32636299
Lancet Infect Dis. 2022 Jul;22(7):e178-e190
pubmed: 35090639
Radiology. 1986 Jul;160(1):85-6
pubmed: 3715050
BMC Infect Dis. 2018 Jan 2;18(1):1
pubmed: 29291713